SA55 Injection Phase II Study in the Treatment of Mild/Moderate COVID-19 Patients

Exclusion Criteria

• •Individuals who are known to be allergic to the investigational drug, any component in the preparation, or other similar drugs;
• •Individuals weighing less than 40 kg;
• •There are comorbidities that require surgery within one month, or comorbidities that are considered life-threatening within one month;
• •Before screening, he has received neutralizing antibody drugs from COVID-19, or received human immunoglobulin or convalescent plasma treatment from convalescent patients within 3 months, or received small molecule drugs from COVID-19 within 7 days;
• •Suspected or confirmed to have combined serious and active bacterial, fungal, viral or other infections (except for COVID-19 infection), such as acute systemic infection, the researcher believes that intervention measures may pose a risk;
• •Individuals who tested positive for influenza A/B virus antigens during screening;
• •Plan to become pregnant within 6 months, already pregnant, or breastfeeding;
• •Participated in clinical trials of other drugs or medical devices within 3 months prior to screening;
• •Having/having suffered from severe neurological disorders (epilepsy, convulsions, or seizures) or mental illness, or having a family history of mental illness;
• •Suffering from/having previously suffered from severe neurological diseases or other serious illnesses that the researcher has determined to be unsuitable for participation in the study (including but not limited to current systemic infections, uncontrolled autoimmune diseases, uncontrolled immunodeficiency diseases, history of myocardial infarction or heart disease, etc.);
• •Unable to cooperate with the follow-up of the study, or unable to guarantee the non use of concomitant drugs/vaccines/treatments prohibited by this protocol during the study period (see section 6.4.2);
• •The researcher believes that due to other reasons, it is not suitable to participate in this study.